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Abstract
To use subharmonic imaging (SHI) to depict the vascularity of pancreatic masses compared to 
contrast-enhanced endoscopic ultrasound (EUS) and pathology.
Sixteen patients scheduled for biopsy of a pancreatic mass were enrolled in an IRB-approved 
study. Pulse-inversion SHI (transmitting/receiving at 2.5/1.25MHz) was performed on a Logiq 9 
system (GE Healthcare, Milwaukee, WI) with a 4C probe, while contrast harmonic EUS 
(transmitting/receiving at 4.7/9.4MHz) was performed with a radial endoscope (GF-UTC180; 
Olympus, Tokyo, Japan) connected to a ProSound SSD α-10 scanner (Hitachi-Aloka, Tokyo, 
Japan). Two injections of the contrast agent Definity (Lantheus Medical Imaging, N Billerica, 
MA) were administrated (0.3–0.4ml and 0.6–0.8ml for EUS and SHI). Contrast-to-tissue ratios 
(CTRs) in the mass and an adjacent vessel were calculated. Four physicians independently scored 
the images (benign to malignant) for diagnostic accuracy and inter-reader agreement.
One subject dropped out before imaging, leaving 11 adenocarcinoma, 1 gastrointestinal stromal 
tumor with pancreatic infiltration and 3 benign masses. Marked subharmonic signals were 
obtained in all subjects with intra-tumoral blood flow clearly visualized using SHI. Significantly 
greater CTRs were obtained in the masses with SHI than with EUS (1.71±1.63 vs 0.63±0.89; 
p=0.016). There were no differences in CTR in the surrounding vessels or when grouped by 
pathology (p>0.60). The accuracies for contrast-EUS and SHI were low (<53%); albeit with a 
greater kappa value for SHI (0.34) than for EUS (0.13).
Diagnostic accuracy of contrast-EUS and trans-abdominal SHI for assessment of pancreatic 
masses was quite low in this pilot study. However, SHI demonstrated improved tumoral CTRs 
relative to contrast-EUS.
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Introduction
With 53,070 new cases expected in 2016, pancreatic adenocarcinoma is among the most 
common cancers diagnosed in the United States [1]. It is the fourth leading cause of cancer-
related death in both men and women, with nearly 41,780 deaths this year and five year 
survival rates at around 5 % [1–3]. One of the reasons that the mortality rate nearly parallels 
the incidence is that only 15 to 20 % of patients are considered resectable at the time of 
diagnosis. Another 20 to 25 % have locally advanced disease that is not amenable to surgical 
resection, and nearly half of patients present with metastatic disease (mainly to the liver) [1, 
4]. Despite the “curative” intent of treatment for patients who present with surgically 
amenable pancreatic cancer, even when undergoing resection followed by adjuvant systemic 
therapy (with or without radiation), their median overall survival is still only 15 months [5]. 
Although endoscopic ultrasound (EUS) is frequently the imaging mode used for managing 
pancreatic cancer [6], to date there are no established guidelines for screening patients at 
high risk for developing pancreatic cancer [4, 6] with tests that are cost effective and have a 
high sensitivity and specificity. Hence, the long-term goal of this project is to develop such a 
screening technique based on contrast enhanced ultrasound (CEUS) imaging.
While contrast-enhanced EUS is a widely used technology in Europe and Asia, it is still not 
standard of care in the United States, due in part to the lack of approved contrast agents and 
contrast-specific EUS imaging equipment [6]. There are currently 3 ultrasound contrast 
agents approved by the United States’ Food and Drug Administration (FDA) for cardiology 
and radiology applications (the latter involves only one contrast agent, which was approved 
as recently as April of 2016). These agents consist of encapsulated gas microbubbles (< 8 
µm in diameter) and have been shown to produce marked nonlinear signals at higher 
acoustic pressures (> 0.5 MPa), which are used in contrast-specific CEUS imaging modes 
[7–9]. Harmonic imaging (HI), transmitting at the fundamental frequency (f0) and receiving 
at the second harmonic (2f0), is one such CEUS imaging technique that is available on many 
commercial ultrasound scanners. However, HI suffers from reduced blood-to-tissue contrast 
caused by second harmonic generation in tissue [10]. Hence, subharmonic imaging (SHI), 
transmitting at the fundamental frequency (f0) and receiving at the subharmonic (f0/2), 
becomes an attractive alternative contrast-specific imaging mode (even with the reduced 
axial resolution relative to HI), due to a lack of subharmonic signals generated by the tissue 
[11–22]. Contrast studies of women with breast lesions (in up to 134 subjects) have 
demonstrated that SHI can detect the neovascularity associated with tumors with greater 
sensitivity than HI [12–14]. Moreover, a study in 45 patients with liver disease has shown 
that SHI can be successfully performed in the abdomen at depths up to 12 cm [15].
Thus, this pilot study investigated the feasibility of using contrast-enhanced, trans-
abdominal SHI to depict pancreatic masses in patients scheduled for an endoscopically 
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guided biopsy of a pancreatic mass. Results were compared to contrast-enhanced EUS as 
well as to pathology.
Material and Methods
Subjects
This pilot study enrolled 16 patients scheduled for an EUS-guided biopsy of a mass located 
in the head of the pancreas. The study was conducted during a 12 month period from May, 
2014 to May of 2015. Before enrollment, each patient gave written informed consent. The 
study was approved by the University’s Institutional Review Board and was compliant with 
the Health Insurance Portability and Accountability Act. The mean age of the patients (9 
female and 7 male) participating in the study was 67 years (range: 27 – 88 years; Table 1).
This study was supported by Lantheus Medical Imaging (N Billerica, MA), which provided 
the ultrasound contrast agent used. However, the authors of this manuscript had sole control 
of the data generated by this trial and the information provided for publication.
Data acquisition
A Logiq 9 scanner (GE Healthcare, Milwaukee, WI) with a 4C probe was modified to 
operate in dual 4.0 MHz grayscale and pulse-inversion, grayscale SHI modes (to allow for 
simultaneous depiction of anatomy and contrast enhanced vascularity) with the latter mode 
transmitting 4 cycle pulses at 2.5 MHz and receiving with a 1 MHz wide bandpass filter 
centered at 1.25 MHz [16]. A 0.5 mm needle hydrophone (Precision Acoustics, UK) was 
used to establish that the maximum acoustic output pressure level was 3.34 MPa (peak to 
peak equivalent to a mechanical index or MI of 0.8) [15]. However, based on our previous 
experiences, the acoustic output power for SHI was kept below 25% (to minimize bubble 
destruction) [17]. The remaining parameters used for image acquisition were selected on an 
individual basis to optimize image quality by a sonographer with more than 15 years of 
experience (MS or TF).
The midline of the pancreatic mass was located (using conventional, individually optimized 
grayscale imaging), while also including some adjacent normal pancreatic tissue in the field 
of view. Prior to injection, lesion size (height, length and width) was measured. For CEUS, 
the midline imaging plane was maintained and the ultrasound contrast agent Definity 
(Lantheus Medical Imaging, N Billerica, MA) was injected (dose: 0.6–0.8 mL) through an 
antecubital vein followed by a 10 mL saline flush. The FDA has approved Definity, which 
consists of phospholipid shelled, octaflouropropane microbubbles approximately 1.1 to 3.3 
µm in diameter [23], for use in echocardiography and it was used off-label in this study. The 
complete contrast wash-in and wash-out was imaged in SHI mode and a digital clip acquired 
(typically 45 – 75 seconds) for subsequent off-line analysis.
Next the subjects were intubated with a radial echoendoscope (GF-UTC180; Olympus, 
Tokyo, Japan) connected to a ProSound SSD α-10 scanner (Hitachi-Aloka, Tokyo, Japan) as 
part of their standard of care. The echoendoscope was advanced until the target lesion was 
identified and its features fully characterized for clinical purposes. Prior to the biopsy, state-
of-the art, contrast harmonic EUS (transmitting at 4.7 MHz and receiving at 9.4 MHz) was 
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performed at low acoustic power (an MI < 0.25) following a second injection of Definity 
(dose: 0.3–0.4 mL) [24, 25]. The time between injections was at least 10 minutes to allow 
the agent to clear the blood pool. A 1–2 minute digital clip of the contrast wash-in and wash-
out was acquired for comparison to SHI and to the biopsy results.
Data analysis
In order to quantify the ability of the two imaging modes to delineate between the mass and 
the normal pancreas, the contrast-to-tissue ratio (CTR) at peak contrast enhancement was 
used. The CTR is defines as [26]:
(1)
where µtand µn represents the mean image signal strength in the target (here the mass) and 
within normal pancreatic tissue, respectively; σ2tand σ2n represents the variance in the 
respective regions calculated based on region-of-interest (ROI) selections. For all subjects 
and both imaging modes, a circular ROI (10 mm in diameter) was placed in the mass and 
compared (one at a time) to 2 ROIs placed within the normal pancreatic tissues using ImageJ 
(v 1.48; NIH, Bethesda, MD) and eqn. (1). Likewise, a 10 mm ROI was placed on an 
adjacent large, normal vessel outside of the mass and compared to the same 2 pancreatic 
tissue ROIs as described above in order to evaluate the impact of contrast concentration. 
Results were compared by location, by imaging mode and by pathology with unpaired t-tests 
assuming a 5 % significance level (using Stata 12; Stata Corp, College Station, TX).
Next, two board-certified gastroenterologists specializing in EUS (with 11 and 17 years of 
experience, respectively) and two board-certified body imaging radiologists (with 14 and 19 
years of experience) blinded to the pathological findings independently evaluated the real-
time CEUS clips (i.e., 2 assessments for contrast EUS and 2 for SHI). The 4 physicians all 
had 10+ years of experience in CEUS. Off-line diagnoses were made based on a five-point 
scale: 1) benign, 2) probably benign, 3) indeterminate, 4) probably malignant, and 5) 
malignant with hypo-enhancing lesions considered more likely to be malignant, while iso- 
and hyper-enhancing masses were considered more benign characteristics [25, 28]. The 
vascular density and morphology relative to the surrounding normal pancreatic tissues were 
also considered. The accuracy of the imaging diagnoses was analyzed using receiver 
operating characteristics (ROC) analyses [27]. Differences between ROC curves were tested 
by computing Mann-Whitney statistics, while inter-reader agreement was assessed by 
calculating the kappa-statistic (using Stata 12).
Results
One subject dropped out before imaging was initiated, leaving 15 subjects with an average 
lesion diameter of 3.07 cm (range: 1.39 – 6.37 cm) who completed this pilot study. The 
pathological reference standard found 11 adenocarcinoma, 1 gastrointestinal stromal tumor 
(GIST) with pancreatic infiltration and 3 benign masses (Table 1). Marked subharmonic 
signals and reasonable tissue-suppression were obtained in all subjects with intra-tumoral 
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blood flow clearly visualized using SHI as demonstrated in the example of Figure 1. While 
larger vessels external to the pancreatic mass were seen with both EUS and SHI, smaller 
neovessels in the mass were more easily visualized with SHI; in spite of the reduced axial 
resolution and deeper scanning depths of SHI relative to EUS (compare Figs. 1b and 1d). 
Moreover, the larger field of view associated with SHI was particularly useful in depicting 
anatomical relationships on a greater scale than EUS, such as the gastric inflow into a GIST 
tumor with pancreatic infiltration (Figure 2).
Significantly greater CTRs were obtained in the pancreatic masses with SHI than with EUS 
(1.71 ± 1.63 vs 0.63 ± 0.89; p = 0.016; Table 2), while there were no differences in CTR 
when comparing the enhancement of the adjacent large, normal vessels (p = 0.72; Table 2). 
Together these results indicate that contrast concentration is not a factor and that trans-
abdominal SHI is able to depict smaller neovessels inside a pancreatic mass better than 
contrast EUS (as also demonstrated in Figure 1). When the CTR values were grouped by 
pathology into benign and malignant cases no statistical differences were found for either 
imaging mode (0.60 ± 0.88 vs 0.64 ± 0.91 and 1.25 ± 2.03 vs 1.63 ± 1.49 for EUS and SHI, 
respectively; p > 0.60). The diagnostic accuracies for contrast EUS and for SHI (in the form 
of the area under the ROC curve – Az) were quite low at 0.09 and 0.52 as well as 0.32 and 
0.45, respectively (Table 3). The Az of one of the EUS readers was lower than those based 
on SHI (p < 0.005). No other Az comparisons were significant (p > 0.05). The inter-reader 
agreement was greater for SHI than for EUS (0.34 vs 0.13; Table 3).
Discussion
In this pilot study, trans-abdominal SHI improved (quantified via the CTR metric) the 
depiction of contrast microbubbles in the small angiogenic neovessels associated with 
pancreatic masses compared to contrast EUS (Figure 1 and Table 2) allowing the tortuous 
morphology of tumor angiogenesis [7] to be visualized in greater detail. Moreover, the 
increased field of view with SHI was shown to be useful for providing a detailed overview of 
the vascular supply to pancreatic lesions (cf., Figure 2). These results are in agreement with 
our prior experiences in breast imaging, where SHI was found to detect tumor 
neovascularity with greater sensitivity than HI (i.e., the technology imbedded in contrast 
EUS) [12–14]. In vivo SHI CTR values of 5.74 ± 1.92 were previously reported by 
Eisenbrey and colleagues [18], which is greater than the 1.71 ± 1.63 measured in this pilot 
study. However, the former CTR values were obtained in an open abdomen canine renal 
model and the discrepancies observed are most likely due to the attenuation and contrast 
concentration (i.e., flow) differences between a human pancreas and a dog kidney. Thus, 
contrast enhanced SHI appears to depict pancreatic masses better than contrast EUS (at least 
for lesions located in the head of the pancreas).
The diagnostic accuracy of SHI and contrast EUS was rather low (Az < 0.55) in this small 
pilot study of 15 subjects (Table 3). Results from this study also demonstrated greater 
agreement between readers of SHI (80 %) compared to EUS (38 %; cf., Table 2). While this 
is (to the best of our knowledge) the first report on SHI of pancreatic cancers in patients, 
contrast EUS has been studied more extensively. One recent study of 147 pancreatic masses 
imaged with contrast EUS reported a sensitivity of 94 % and a specificity of 71 % [25]. A 
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meta-analysis of 12 studies involving 1139 patients found a similar diagnostic accuracy of 
0.97 based on ROC analysis with a pooled sensitivity and specificity of 94 % and 89 %, 
respectively [28]. Most likely the small sample size in this pilot study accounts for most of 
these differences.
Nonetheless, these results indicate that the clinical niche for SHI may be earlier in the 
management of pancreatic lesions. Currently, contrast enhanced computed tomography (CT) 
is used as the first line imaging modality for the pancreas [29]. However, ultrasound 
microbubble based contrast agents are exceptionally safe vascular tracers and, unlike CT 
with contrast, have very few contraindications (typically involving allergies to the gas 
encapsulation material) and involve no radiation. Moreover, the higher frame rates (i.e., 
temporal resolution) of ultrasound (including SHI) relative to CT will permit better 
quantification of blood flow kinetics. Finally, the sensitivity and specificity for CT detection 
of pancreatic masses is reported to range from 68 % to 86 % and from 50 % to 64 % making 
it lower than that of contrast EUS reported in the literature (94% and 89%, respectively) [28, 
29]. Consequently, SHI may be a better imaging mode for the initial assessment of 
pancreatic lesions followed by a biopsy under EUS guidance (if required) and future studies 
should compare SHI and CT for this application.
Additionally, the improved depiction of pancreatic tumor neovascularity may be useful in 
determining whether or not a lesion is resectable as well as monitoring response to treatment 
in patients not eligible for surgical resection. If there are no distant metastases, the decision 
to resect a pancreatic tumor or not is largely driven by which vessels are involved (most 
critically the superior mesenteric artery and vein as well as the celiac and hepatic arteries) 
[29, 30]. These assessments can sometimes be difficult to resolve with CT or MRI and 
CEUS might improve specificity. This will be a topic for future investigations.
In conclusion, contrast enhanced SHI can potentially be employed as an imaging tool for 
identifying the vascularity of pancreatic masses. In this pilot study, SHI demonstrated 
improved tumoral CTRs relative to contrast EUS. However, the diagnostic accuracy of both 
contrast EUS and trans-abdominal SHI for assessment of pancreatic masses was quite low in 
this small population. While the long-term aim of this project is to develop a CEUS based 
screening technique for patients at high risk of developing pancreatic adenocarcinoma, it is 
first necessary to establish the utility of CEUS/SHI in characterizing pancreatic lesions, 
before beginning a trial to investigate whether these techniques aide in lesion detection. 
Hence, future efforts should initially be directed at comparing CT and SHI for imaging 
pancreatic masses or for monitoring the treatment response of pancreatic adenocarcinoma 
with SHI.
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Figure 1. 
A pancreatic adenocarcinoma (arrowheads) scanned in dual grayscale/SHI mode (SHI is 
depicted in golden hues on the right) before (a) and after (b) injection of Definity. The size 
of this tumor was approximately 3.0×4.0×4.4 cm. The same lesion depicted in contrast EUS 
mode before (c) and after (d) contrast administration. Notice, the larger vessels (large 
arrows) external to the cancer seen with both EUS and SHI, while smaller neovessels inside 
the mass are more prominent in SHI mode (small arrows).
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Figure 2. 
Large GIST tumor with pancreatic infiltration (around 6.4 cm in diameter; arrowheads) 
imaged with dual grayscale/SHI (SHI is depicted in golden hues on the right) (a) pre-
contrast administration, (b) 21.25 seconds after Definity injection as the initial microbubbles 
appear outside the pancreas (arrows) and (c) 0.5 seconds later the bubbles are seen spreading 
deeper into the mass (arrows) followed by (d) complete enhancement of the tumor 3 seconds 
later (24.25 seconds post-injection).
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Table 1
Patient population and biopsy results
Patient ID Gender Age (years) Tumor
diameter (cm)
Diagnosis
1 F 78 3.65 adenocarcinoma
2 M 75 2.33 adenocarcinoma
3 M 61 2.93 adenocarcinoma
4 F 71 2.01 adenocarcinoma
5 M 72 3.56 adenocarcinoma
6 F 61 2.30 chronic pancreatitis
7 M 88 2.26 adenocarcinoma
8 M 27 6.37 GIST with pancreatic infiltration
9 F 68 5.31 duodenitis & hyperplasia
10 F 65 3.27 adenocarcinoma
11 F 67 3.73 adenocarcinoma
12 F 70 3.48 chronic inflammation & fibrosis with gastric infiltration
13 F 76 2.75 adenocarcinoma
14 M 67 3.27 adenocarcinoma
15 F 55 4.36 adenocarcinoma
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Table 2
CTR values for EUS and SHI comparisons.
CTR EUS SHI p-value
mass vs tissue 0.63 ± 0.89 1.71 ± 1.63 0.016
vessel vs tissue 5.50 ± 5.69 5.01 ± 3.85 0.72
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Table 3
Diagnostic accuracy (ROC analysis) and inter-reader agreement.
EUS SHI
Reader 1 Reader 2 Reader 3 Reader 4
Az 0.52 0.09* 0.33 0.46
κ (% agreement) 0.13 (38 %) 0.34 (80 %)
*p < 0.005 vs. SHI (i.e., reader 2 vs. readers 3 or 4).
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